DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bontril PDM (Phendimetrazine Tartrate) - Summary



BONTRIL PDM (phendimetrazine tartrate) is a sympathomimetic amine with pharmacological activity similar to the prototype drugs of this class used in obesity, the amphetamines.

Bontril PDM (phendimetrazine tartrate) is indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. The limited usefulness of agents of this class (see CLINICAL PHARMACOLOGY) should be measured against possible risk factors inherent in their use such as those described below.

See all Bontril PDM indications & dosage >>


Media Articles Related to Bontril PDM (Phendimetrazine)

FDA Panel Endorses Liraglutide as Obesity Treatment
Source: Medscape Diabetes & Endocrinology Headlines [2014.09.12]
An FDA committee voted 14 to 1 in favor of liraglutide as an obesity treatment, stipulating that lingering safety questions be addressed in postmarketing studies.
Medscape Medical News

FDA Approves New Obesity Drug
Source: MedicineNet Obesity (Weight Loss) Specialty [2014.09.12]
Title: FDA Approves New Obesity Drug
Category: Health News
Created: 9/11/2014 12:36:00 PM
Last Editorial Review: 9/12/2014 12:00:00 AM

Third Obesity Drug Wins FDA Okay
Source: MedPage Today Cardiovascular [2014.09.11]
(MedPage Today) -- Following an earlier snub, the FDA finally approved the weight-loss drug Contrave, a combination of bupropion and naltrexone, the agency announced.

FDA Approves Bupropion/Naltrexone (Contrave) for Obesity
Source: Medscape Diabetes & Endocrinology Headlines [2014.09.10]
After a rocky start, the FDA has finally approved the obesity medication, but with a boxed warning about the risk for suicidal thoughts and serious neuropsychiatric events.
FDA Approvals

'Fingerprinting' cell metabolism points toward study of obesity, diabetes
Source: Cholesterol News From Medical News Today [2014.09.10]
Researchers have shown how to use a new imaging platform to map lipid metabolism in living cells, discovering specifically where cholesterol is stored and pointing toward further studies in...

more news >>

Published Studies Related to Bontril PDM (Phendimetrazine)

Rare case of rhabdomyolysis with therapeutic doses of phendimetrazine tartrate. [2006.03]
Phendimetrazine tartrate is a newer drug that acts as a central stimulant and indirectly acting sympathomimetic with a host of uses similar to the class amphetamines... Additional awareness is needed to educate their patients about the side effects associated with these drugs and to strongly discourage their unsupervised use.

Acute interstitial nephritis following treatment with anorectic agents phentermine and phendimetrazine. [1998.10]
A 47-year-old mildly obese female began a weight reduction program that included anorectic therapy with phentermine and phendimetrazine. A normal urinalysis and serum creatinine were documented at the start of therapy... This case represents the first report of acute interstitial nephritis associated with phentermine or phendimetrazine.

A simple gas chromatographic identification and determination of 11 CNS stimulants in biological samples. Application on a fatality involving phendimetrazine. [1989.02]
A method is presented for the simultaneous identification and quantification of several CNS stimulants, including amphetamine in plasma and urine by GC/FID using mephentermine as an internal standard.

Fatality from illicit phendimetrazine use. [1988]
Phendimetrazine is an anorectic agent which recently has been detected in three medical examiner's cases. In one instance death was attributed to this drug... In the one instance where death was attributed to this substance, the blood concentration was 300 ng/ml.

more studies >>

Page last updated: 2014-09-12

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014